MA39849A - Souches de listeria utilisées comme vaccin recombinant et procédé de production - Google Patents

Souches de listeria utilisées comme vaccin recombinant et procédé de production

Info

Publication number
MA39849A
MA39849A MA039849A MA39849A MA39849A MA 39849 A MA39849 A MA 39849A MA 039849 A MA039849 A MA 039849A MA 39849 A MA39849 A MA 39849A MA 39849 A MA39849 A MA 39849A
Authority
MA
Morocco
Prior art keywords
recombinant
recombinant listeria
producing
methods
same
Prior art date
Application number
MA039849A
Other languages
English (en)
Inventor
Robert Petit
Anu Wallecha
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MA39849A publication Critical patent/MA39849A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés de traitement, de protection contre une tumeur ou un cancer et d'induction d'une réponse immunitaire contre cette tumeur ou ce cancer, comprenant l'étape d'administration à un patient d'une souche de listeria recombinante comportant un acide nucléique codant pour une protéine prfa mutante qui assure la restauration partielle de la fonction prfa.
MA039849A 2014-04-24 2015-04-14 Souches de listeria utilisées comme vaccin recombinant et procédé de production MA39849A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983732P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
MA39849A true MA39849A (fr) 2017-03-01

Family

ID=54333010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039849A MA39849A (fr) 2014-04-24 2015-04-14 Souches de listeria utilisées comme vaccin recombinant et procédé de production

Country Status (15)

Country Link
US (2) US10258679B2 (fr)
EP (1) EP3134510B1 (fr)
JP (3) JP7009061B2 (fr)
KR (2) KR102359691B1 (fr)
CN (1) CN106459887A (fr)
AU (1) AU2015250111A1 (fr)
BR (1) BR112016024352A2 (fr)
CA (1) CA2946716A1 (fr)
IL (1) IL248483A0 (fr)
MA (1) MA39849A (fr)
MX (1) MX2016013985A (fr)
RU (1) RU2016145464A (fr)
SG (2) SG10202011841WA (fr)
TW (2) TWI692525B (fr)
WO (1) WO2015164121A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP2683400A4 (fr) 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
WO2015126921A1 (fr) 2014-02-18 2015-08-27 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
WO2015164121A1 (fr) 2014-04-24 2015-10-29 Advaxis, Inc. Souches de listeria utilisées comme vaccin recombinant et procédé de production
MX2017004729A (es) * 2014-10-14 2018-01-09 Univ Pennsylvania Terapia de combinacion para usar en la terapia contra el cancer.
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN106978381A (zh) * 2017-03-23 2017-07-25 上海理工大学 prfA基因缺失单核细胞增生李斯特氏菌及制备方法
MX2020003100A (es) 2017-09-19 2020-08-20 Advaxis Inc Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
CA3080835A1 (fr) 2017-10-31 2019-05-09 Pantarhei Bioscience B.V. Methodes immunotherapeutiques pour traiter et/ou prevenir le cancer du poumon
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
MX2020009405A (es) * 2018-03-09 2021-01-08 Advaxis Inc Composiciones y métodos para evaluar la atenuación y la infectividad de cepas de listeria.
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021259963A1 (fr) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunisation contre wnt4 pour le traitement et la prophylaxie du cancer du sein
WO2023066923A1 (fr) 2021-10-19 2023-04-27 Rahman Nafis Contraception masculine

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (fr) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Utilisation des peptides prokaryotic pest-like pour augmenter l'immunogénicité des antigènes
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
CA2512812A1 (fr) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methodes et trousses renforcant l'immunogenecite d'un vecteur de vaccin bacterien
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
DK2942391T3 (en) 2004-08-13 2018-08-27 Univ Pennsylvania PROCEDURES FOR THE MANUFACTURE OF ANTIBIOTICS-RESISTANCE-FREE VACCINES
AU2005295158A1 (en) * 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
EP2977456B1 (fr) 2006-08-15 2017-10-25 The Trustees Of The University Of Pennsylvania Compositions comprenant un hmw-maa et fragments de celui-ci pour le traitement du cancer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008130551A2 (fr) 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Souche de listeria exempte de résistance aux antibiotiques et procédé pour la construction et l'utilisation de celle-ci
WO2009143085A1 (fr) * 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procédés d'utilisation
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2288379A4 (fr) 2008-05-19 2012-08-08 Advaxis Système de double distribution pour des antigènes hétérologues
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
KR20110045010A (ko) * 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011100754A1 (fr) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
WO2012138377A2 (fr) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania Utilisation de vecteurs de vaccin de listeria pour renverser l'insensibilité au vaccin chez des individus infectés par des parasites
WO2012068360A1 (fr) 2010-11-17 2012-05-24 Aduro Biotech Procédés et compositions pour l'induction d'une réponse immunitaire vis-à-vis d'egfrviii
EP2683400A4 (fr) * 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
WO2015126921A1 (fr) 2014-02-18 2015-08-27 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
CA2940646A1 (fr) 2014-02-25 2015-09-03 Advaxis, Inc. Compositions et methodes pour le traitement de tumeurs a surexpression de her2/neu
CA2941405A1 (fr) 2014-03-05 2015-09-11 Advaxis, Inc. Procedes et compositions pour accroitre le rapport des lymphocytes t effecteurs aux lymphocytes t regulateurs
WO2015164121A1 (fr) 2014-04-24 2015-10-29 Advaxis, Inc. Souches de listeria utilisées comme vaccin recombinant et procédé de production
CN106794234A (zh) 2014-05-02 2017-05-31 宾夕法尼亚大学理事会 用于治疗her‑2阳性癌症的联合免疫疗法和放疗
CN114984228A (zh) 2014-07-18 2022-09-02 阿德瓦希斯股份有限公司 用于治疗***癌的pd-1拮抗剂和基于李斯特菌的疫苗的组合
SG11201700090RA (en) 2014-07-18 2017-02-27 Advaxis Inc Listeria-based immunogenic compositions for eliciting anti-tumor responses
WO2016011320A1 (fr) 2014-07-18 2016-01-21 Advaxis, Inc. Système de largage d'antigènes hétérologues bivalent dérivé de listéria
SG11201700092XA (en) 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
MX2017004729A (es) 2014-10-14 2018-01-09 Univ Pennsylvania Terapia de combinacion para usar en la terapia contra el cancer.
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
WO2016126878A2 (fr) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Immunomodulation reposant sur listeria
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126876A2 (fr) 2015-02-03 2016-08-11 Advaxis, Inc. Adjuvants à base de listeria
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (fr) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement d'un cancer du pancréas
US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof
CN107847611A (zh) 2015-05-26 2018-03-27 阿德瓦希斯公司 个性化的基于递送载体的免疫疗法及其用途
CN108138099A (zh) 2015-06-24 2018-06-08 阿德瓦希斯公司 用于个性化的基于递送载体的免疫疗法的制造装置和方法
MA42841A (fr) 2015-09-15 2018-07-25 Advaxis Inc Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison
WO2017048850A1 (fr) 2015-09-15 2017-03-23 Advaxis, Inc. Compositions immunogènes à base de listeria et procédés pour les utiliser dans la prévention et le traitement du cancer
AU2016324170A1 (en) 2015-09-17 2018-04-12 Advaxis, Inc. Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
MA43124A (fr) 2015-10-14 2018-09-05 Advaxis Inc Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
WO2017085691A1 (fr) 2015-11-20 2017-05-26 Advaxis, Inc. Procédé et dispositif de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria recombinante
TW201726171A (zh) 2015-12-16 2017-08-01 艾***公司 以李斯特菌屬為主的免疫治療及其用法
CN108884468A (zh) 2016-01-27 2018-11-23 阿德瓦希斯公司 基于个性化递送载体的免疫疗法及其用途
CA3029235A1 (fr) 2016-07-05 2018-01-11 Advaxis, Inc. Compositions immunogenes a base de listeria comprenant des antigenes de proteine tumorale de wilms et procedes d'utilisation correspondants
WO2018085854A1 (fr) 2016-11-07 2018-05-11 Advaxis, Inc. Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
WO2018129306A1 (fr) 2017-01-05 2018-07-12 Advaxis, Inc. Souches vaccinales de listeria recombinées et leurs méthodes d'utilisation en immunothérapie anticancéreuse

Also Published As

Publication number Publication date
US20190240303A1 (en) 2019-08-08
US20170042996A1 (en) 2017-02-16
WO2015164121A1 (fr) 2015-10-29
MX2016013985A (es) 2017-01-11
JP7009061B2 (ja) 2022-01-25
KR102491332B1 (ko) 2023-01-27
EP3134510A4 (fr) 2018-04-25
TWI722858B (zh) 2021-03-21
US10258679B2 (en) 2019-04-16
CA2946716A1 (fr) 2015-10-29
KR20160145627A (ko) 2016-12-20
EP3134510A1 (fr) 2017-03-01
CN106459887A (zh) 2017-02-22
KR102359691B1 (ko) 2022-02-10
JP7300041B2 (ja) 2023-06-28
JP2022105768A (ja) 2022-07-14
IL248483A0 (en) 2016-12-29
BR112016024352A2 (pt) 2018-01-23
JP2020099352A (ja) 2020-07-02
TW201546276A (zh) 2015-12-16
KR20220021021A (ko) 2022-02-21
TW202041671A (zh) 2020-11-16
JP2017513502A (ja) 2017-06-01
RU2016145464A (ru) 2018-05-24
AU2015250111A1 (en) 2016-12-08
EP3134510B1 (fr) 2023-11-01
SG10202011841WA (en) 2021-01-28
SG11201608820WA (en) 2016-11-29
TWI692525B (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
MX2016013985A (es) Cepas de vacunas de listeria recombinante y metodos para producir las mismas.
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2017004729A (es) Terapia de combinacion para usar en la terapia contra el cancer.
MX2017000836A (es) Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
MX2016010565A (es) Inmunoterapia del cancer a través de la combinacion de estimulacion inmunatoria local y sistemica.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
NZ745327A (en) Whole-cell cancer vaccines and methods for selection thereof
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
NZ725212A (en) Group a streptococcus vaccine
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
MX365560B (es) Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes.
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
MX2019007924A (es) Vacunas contra la influenza.
MX2021004453A (es) Nuevos antigenos y metodos contra el cancer.
WO2016011432A3 (fr) Identification de peptides immunogènes de classe ii du complexe majeur d&#39;histocompatibilité pour une immunothérapie
MX2017016438A (es) Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit.